Heartbeam, Inc. Form 4 Filings

Cruickshank Tim reported acquisition or exercise transactions in this Form 4 filing.

HeartBeam, Inc. reported that CFO Tim Cruickshank received a grant of 167,760 shares of common stock in the form of Restricted Stock Units on July 24, 2026 under the 2022 Equity Incentive Plan. The RSUs vested in full on the grant date as shares-in-lieu-of-cash for the 2025 Bonus Program, increasing his directly held shares to 239,990.

Vajdic Branislav reported acquisition or exercise transactions in this Form 4 filing.

HeartBeam, Inc. reported equity awards to President and director Branislav Vajdic under its 2022 Equity Incentive Plan. On June 15, 2026 he was granted 2,800,000 performance-based PRSUs that vest over three years upon achievement of milestones and continued service. On July 24, 2026 he received 260,870 RSUs, which vested in full on the grant date and settled his 2025 bonus in shares instead of cash.

HeartBeam, Inc. director Richard Ferrari increased his stake by purchasing 57,500 shares of common stock at $0.80 per share. The buy was made in connection with HeartBeam’s underwritten public offering of 12,500,000 common shares, for which Titan Partners acted as sole bookrunner.

This amended Form 4 corrects Ferrari’s previously reported acquisition and total beneficial ownership. The original filing mistakenly showed 62,500 shares acquired; the correct figure is 57,500 shares. Following this transaction, Ferrari beneficially owns 286,636 shares of HeartBeam common stock directly.

HeartBeam, Inc. CFO Tim Cruickshank increased his stake by buying 31,250 shares of common stock at $0.80 per share. The purchase was made in connection with HeartBeam’s underwritten public offering of 12,500,000 shares of common stock.

The offering priced on April 14, 2026 and closed on April 16, 2026, with Titan Partners, a division of American Capital Partners, acting as sole bookrunner. After this transaction, Cruickshank directly owns 72,230 shares, including 23,333 RSUs that have vested.

HeartBeam, Inc. director Willem Elfrink reported an open-market purchase of common stock. On April 16, 2026, he bought 187,500 shares at $0.80 per share, bringing his direct holdings to 538,667 shares.

According to the footnote, these shares were purchased in connection with HeartBeam’s underwritten public offering of 12,500,000 shares of common stock, which priced on April 14, 2026 and closed on April 16, 2026, with Titan Partners acting as sole bookrunner.

HeartBeam, Inc. director-associated entity Open Book Healthcare purchased 31,250 shares of common stock in an open-market transaction on April 16, 2026, at $0.80 per share. The purchase was made in connection with HeartBeam’s underwritten public offering of 12,500,000 shares of common stock, which priced on April 14, 2026 and closed on April 16, 2026. Following this transaction, 31,250 shares are held indirectly for the benefit of Michael R. Jaff through Open Book Healthcare.

HeartBeam, Inc. director Branislav Vajdic made an open-market purchase of 31,250 shares of common stock at $0.80 per share. After this transaction, he directly owns 909,914 shares.

The shares were bought in connection with HeartBeam’s underwritten public offering of 12,500,000 common shares, for which Titan Partners, a division of American Capital Partners, acted as sole bookrunner. The offering priced on April 14, 2026 and closed on April 16, 2026.

HeartBeam, Inc. director Richard Ferrari reported an open-market purchase of 62,500 shares of common stock at $0.80 per share. Following this buy, he directly holds 291,636 shares. The purchase was made in connection with HeartBeam’s underwritten public offering of 12,500,000 common shares, which priced on April 14, 2026 and closed on April 16, 2026.

HeartBeam, Inc. President Robert Paul Eno reported an open-market purchase of common stock. On April 16, 2026, he bought 12,500 shares at $0.80 per share, increasing his direct holdings to 36,742 shares.

The purchased shares were acquired in connection with HeartBeam’s underwritten public offering of 12,500,000 shares of common stock, which priced on April 14, 2026 and closed on April 16, 2026. His reported holdings include 23,333 RSUs that have vested as referenced in a prior Form 4 filing.

HeartBeam, Inc. director Marga Ortigas-Wedekind purchased 25,000 shares of Common Stock on April 16, 2026 in an open-market transaction at $0.80 per share, bringing her direct holdings to 137,293 shares.

According to a footnote, these shares were bought in connection with HeartBeam’s underwritten public offering of 12,500,000 shares of common stock. Titan Partners, a division of American Capital Partners, acted as the sole bookrunner for this offering, which priced on April 14, 2026 and closed on April 16, 2026.

HeartBeam, Inc. director-associated entities acquired 750,000 shares of common stock at $0.80 per share in an underwritten public offering of 12,500,000 shares. The purchase was an open-market style transaction tied to the offering that priced on April 14, 2026 and closed on April 16, 2026.

The shares are held by Strome Mezzanine Fund II, LP, the Mark E. Strome Living Trust and Strome Dynasty, LLC. Following this transaction, entities associated with director Mark E. Strome hold 3,650,000 shares of HeartBeam common stock indirectly. Mr. Strome has voting and disposal authority but disclaims beneficial ownership beyond his pecuniary interest.

HeartBeam, Inc. director Marga Ortigas-Wedekind received a grant of stock options representing the right to buy 44,827 shares of common stock at an exercise price of $1.43 per share. This is a compensation-related award, not an open-market share purchase or sale.

According to the grant terms, one half of the options, covering 22,413.5 underlying shares, will vest on March 31, 2026, and the remaining half will vest on June 30, 2026. The options were issued under HeartBeam’s 2022 Equity Incentive Plan and expire on January 1, 2036, giving the director a long-term incentive tied to the company’s share performance.

HeartBeam, Inc. director Richard Ferrari reported an equity award of 50,000 shares of common stock in the form of restricted stock units. The grant was made on February 9, 2026 and increased his directly held position to 229,136 shares.

According to the award terms, one half of the RSU shares will vest on March 31, 2026, and the remaining half will vest on June 30, 2026, based on a vesting commencement date of January 1, 2026. The RSUs were issued under HeartBeam’s 2022 Equity Incentive Plan and carry no cash exercise price.

HeartBeam, Inc. reported that major shareholder Mark E. Strome received a grant of stock options to acquire 41,380 shares of common stock at an exercise price of $1.43 per share. Half of these options vest on March 31, 2026 and the remaining half on June 30, 2026, with an expiration date of January 1, 2036. The options were issued under HeartBeam’s 2022 Equity Incentive Plan and represent compensation rather than an open-market purchase or sale.

HeartBeam, Inc. director receives equity award. Director Michael R. Jaff acquired 20,689 shares of HeartBeam common stock as a grant of restricted stock units (RSUs) at no cash cost on February 9, 2026. Following this award, he holds 95,809 shares directly.

The RSUs were granted under the company’s 2022 Equity Incentive Plan. One half of the shares subject to this special RSU grant are scheduled to vest on March 31, 2026, with the remaining half scheduled to vest on June 30, 2026, subject to the stated vesting terms.

HeartBeam, Inc. reported that President and director Branislav Vajdic received a grant of options to buy 61,932 shares of common stock at an exercise price of $1.45 per share. The options were granted on February 9, 2026 and expire on January 1, 2036.

According to the vesting terms, one half of the shares subject to this special option will vest on March 31, 2026, with the remaining shares vesting on June 30, 2026, based on a vesting commencement date of January 1, 2026. After this grant, Vajdic holds options for 61,932 underlying shares under the company’s 2022 Equity Incentive Plan.

HeartBeam, Inc. reported a routine equity compensation grant to its CFO, Tim Cruickshank. He received stock options covering 53,104 shares of common stock at an exercise price of $1.45 per share. Half of these options vest on March 31, 2026 and the remainder on June 30, 2026 under the 2022 Equity Incentive Plan.

HeartBeam, Inc. director Willem Elfrink received a stock option grant covering 51,724 shares of common stock on February 9, 2026. The options have an exercise price of $1.43 per share and expire on January 1, 2036.

According to the vesting terms, half of the shares subject to this “Special Option” vest on March 31, 2026, with the remaining half vesting on June 30, 2026, based on a vesting commencement date of January 1, 2026. The options were issued under HeartBeam’s 2022 Equity Incentive Plan and represent Elfrink’s reported derivative holdings following this award.

Nelson Kenneth Warwick III reported acquisition or exercise transactions in this Form 4 filing.

HeartBeam, Inc. director Nelson Kenneth Warwick III reported a compensation grant of 17,241 restricted stock units (RSUs) of common stock. These RSUs were granted on February 9, 2026 at no cash cost and increase his direct holdings to 144,388 shares.

According to the grant terms, one half of the RSUs will vest on March 31, 2026, and the remaining half will vest on June 30, 2026, based on a vesting commencement date of January 1, 2026. The award was issued under HeartBeam’s 2022 Equity Incentive Plan, highlighting routine equity-based director compensation rather than an open-market purchase.

HeartBeam, Inc. director George de Urioste received a grant of options to acquire 51,724 shares of common stock at an exercise price of $1.43 per share. Following this award, he holds options covering 51,724 shares.

According to the grant terms, one half of the shares subject to this "Special Option" vest on March 31, 2026, with the remaining half vesting on June 30, 2026, based on a vesting commencement date of January 1, 2026. The options expire on January 1, 2036 and were issued under HeartBeam’s 2022 Equity Incentive Plan.

HeartBeam, Inc. reported that President Robert Paul Eno received an option grant covering 55,172 shares of common stock at an exercise price of $1.45 per share. The award, granted on February 9, 2026, vests half on March 31, 2026 and the remainder on June 30, 2026, and expires on January 1, 2036. These options were issued under the company’s 2022 Equity Incentive Plan and represent equity-based compensation rather than an open-market stock purchase.

HeartBeam, Inc. (BEAT) CFO Tim Cruickshank reported a Form 4 showing a sale of 17,647 shares of Common Stock and a grant of 23,333 Restricted Stock Units (RSUs) on 09/30/2025. The RSUs were issued under the company’s 2022 Equity Incentive Plan and vest in two equal tranches: one half on the three‑month anniversary of the vesting commencement date (July 1, 2025 start) and the remainder on the six‑month anniversary. The filing notes RSUs do not expire and are either vested or canceled. The report was signed by the reporting person on 10/03/2025.

Richard Ferrari, a director of HeartBeam, Inc. (BEAT), filed a Form 4 reporting changes in his beneficial ownership. The filing shows 65,653 shares of common stock held indirectly through the Ferrari Living Trust and a disposition of 179,136 shares. The report also records two restricted stock unit/award grants: 80,645 RSUs awarded on July 11, 2025 and 43,939 RSUs granted on September 30, 2025.

The July RSUs vest 100% on the earlier of July 11, 2026 or the issuer's 2026 annual meeting, subject to continued service as an Outside Director. The September RSUs vest in two tranches: one half at three months and the remainder at six months from the vesting commencement date (July 1, 2025). The July RSUs are described as restricted stock units that do not expire and convert to one share each upon vesting.

HeartBeam, Inc. (BEAT) reporting person George de Urioste disclosed changes in beneficial ownership on 07/11/2025. The filing shows a disposition of 57,146 shares of common stock and a grant of 60,483 restricted stock units (RSUs) that vest 100% on the earlier of 07/11/2026 or the company's 2026 annual meeting, subject to continued service as an Outside Director. The report also lists a derivative position: a special option with a $1.65 exercise price covering 45,454 shares (total underlying common stock shown as 89,454 following the transactions). The RSUs do not expire; the option has exercise and vesting timing described in remarks.

Mark E. Strome, a director of HeartBeam, Inc. (BEAT), reported transactions showing an indirect holding of 3,150,000 shares held by affiliated entities and a direct sale of 57,146 shares on 07/01/2025. The filing states Mr. Strome has authority to vote and dispose of the shares held by Strome Mezzanine Fund II, LP, Mark E. Strome Living Trust, and Strome Dynasty, LLC, and disclaims beneficial ownership except for his pecuniary interest.

The report also discloses equity awards: 60,483 restricted stock units granted on 07/11/2025 that vest on the earlier of 07/11/2026 or the 2026 annual meeting (subject to continued service as an Outside Director), and options covering 36,364 shares with an exercise price of $1.65 (granted 09/30/2025) and a vesting schedule tied to the July 1, 2025 commencement date. The filing is signed by Mr. Strome on 10/02/2025.

Branislav Vajdic, listed as Chief Executive Officer and director of HeartBeam, Inc. (BEAT), reported changes in his beneficial ownership. The filing shows a disposition of 878,664 shares of common stock and reports beneficial ownership of 1,428,424 common shares following the reported transactions. The report also discloses derivative securities: options with a $1.65 exercise price tied to 54,424 underlying common shares and an indicated date of 07/01/2035. An explanatory note states options were granted on September 30, 2025 and vesting occurs in two tranches after a July 1, 2025 vesting commencement date. The form is signed by Mr. Vajdic on 10/02/2025.

Marga Ortigas-Wedekind, a director of HeartBeam, Inc. (BEAT), reported multiple transactions on this Form 4. The filing shows a disposition of 112,293 shares of common stock and remaining beneficial ownership entries including 16,824 shares held indirectly. The reporting person received 60,483 restricted stock units (RSUs) granted on July 11, 2025; those RSUs vest 100% on the earlier of July 11, 2026 or the company’s 2026 annual meeting, subject to continued service as an Outside Director. The filing also discloses a stock option covering 39,394 underlying shares with an exercise price of $1.65 and an indicated post-transaction derivative beneficial ownership total of 83,029 shares. The RSUs are non-expiring (vest or cancel) and the option vesting schedule references a July 1, 2025 commencement with staged vesting.

Willem Elfrink, a director of HeartBeam, Inc. (BEAT), reported transactions dated 07/11/2025 on a Form 4 filed for changes in beneficial ownership. The filing shows 106,825 shares held indirectly by the Elfrink Living Trust and a reported disposition of 351,167 shares of Common Stock. The reporting person received 60,483 restricted stock units (RSUs) on 07/11/2025, which vest 100% on the earlier of 07/11/2026 or the company's 2026 annual meeting if he remains an Outside Director. The filing also discloses stock options covering 45,454 shares with a stated exercise price of $1.65; the explanatory text references a grant on 09/30/2025 and vesting tied to a 07/01/2025 commencement date per the company’s 2022 Equity Incentive Plan. The Form is signed by Mr. Elfrink on 10/02/2025.